Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)

Clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria. It is also indicated for the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci.

Sagent Pharmaceuticals, Inc. announced U.S. FDA approval of Clindamycin Injection, USP, an antibiotic used to treat bacterial infections. Sagent's latex-free clindamycin will be available in three single-dose vial sizes and in pharmacy bulk packaging. According to IMS, the 2011 U.S. market for injectable clindamycin approximates $65 million. SGNT expects to launch the product in early 2012. As with all products in Sagent's portfolio, clindamycin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. SGNT has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.

For more information about Sagent Pharmaceuticals, Inc. please visit http://www.sagentpharma.com

Read full artical and disclimar at : http://doubleinstocks.com/?p=18835